Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Bitcoin USD

    70,423.09
    +369.18 (+0.53%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,950.42
    +18.44 (+0.23%)
     
  • Gold

    2,228.70
    +16.00 (+0.72%)
     
  • Crude Oil

    82.72
    +1.37 (+1.68%)
     
  • 10-Yr Bond

    4.2280
    +0.0320 (+0.76%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules

FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules

Millions of Americans who would like to lower their risk of a heart attack could have a new, low-cost option to help them. On Friday, the FDA approved 1 gram Icosapent Ethyl Capsules from Hikma Pharmaceuticals (OTC: HKMPY). Hikma's capsules are the generic equivalent of Vascepa from Amarin (NASDAQ: AMRN), a branded fish oil product expected to drive billions in annual sales.